The study tested BMS’ Opdivo with concurrent chemoradiotherapy followed by both Opdivo and Yervoy or Opdivo by itself. Researchers compared outcomes from that cohort to chemoradiotherapy followed by durvalumab.
Opdivo has about two dozen approved cancer indications, with some of them including antibody Yervoy. This trial focused on 925 patients with unresectable stage III non-small cell lung cancer.
The drugmaker said it will work with investigators to share more findings from the study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
